BRPI0913949A2 - preparação e composição de proteínas inibidoras inter-alfa a partir de sangue - Google Patents

preparação e composição de proteínas inibidoras inter-alfa a partir de sangue

Info

Publication number: BRPI0913949A2
Authority: BR; Brazil
Prior art keywords: inter; blood; preparation; composition; alpha inhibitor
Prior art date: 2008-05-28

Application number

BRPI0913949A

Other languages

English (en)

Inventor

Edward S Sirya

Peter Brne

Yow-Pin Lim

Original Assignee

Pro Thera Biolog Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-28

Filing date

2009-05-28

Publication date

2015-10-20

2009-05-28 Application filed by Pro Thera Biolog Llc filed Critical Pro Thera Biolog Llc

2009-05-28 Priority to BR122020017577-0A priority Critical patent/BR122020017577B1/pt

2015-10-20 Publication of BRPI0913949A2 publication Critical patent/BRPI0913949A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Analytical Chemistry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BRPI0913949A 2008-05-28 2009-05-28 preparação e composição de proteínas inibidoras inter-alfa a partir de sangue BRPI0913949A2 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122020017577-0A BR122020017577B1 (pt)	2008-05-28	2009-05-28	Método para purificar proteínas inibidoras inter-alfa

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13026908P	2008-05-28	2008-05-28
PCT/US2009/003291 WO2009154695A1 (en)	2008-05-28	2009-05-28	Preparation and composition of inter-alpha inhibitor proteins from blood

Publications (1)

Publication Number	Publication Date
BRPI0913949A2 true BRPI0913949A2 (pt)	2015-10-20

Family

ID=41434346

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0913949A BRPI0913949A2 (pt)	2008-05-28	2009-05-28	preparação e composição de proteínas inibidoras inter-alfa a partir de sangue
BR122020017577-0A BR122020017577B1 (pt)	2008-05-28	2009-05-28	Método para purificar proteínas inibidoras inter-alfa

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122020017577-0A BR122020017577B1 (pt)	2008-05-28	2009-05-28	Método para purificar proteínas inibidoras inter-alfa

Country Status (13)

Country	Link
US (3)	US9139641B2 (pt)
EP (1)	EP2291654B1 (pt)
JP (3)	JP5793076B2 (pt)
KR (3)	KR101828433B1 (pt)
CN (2)	CN102112876B (pt)
AU (1)	AU2009260822B2 (pt)
BR (2)	BRPI0913949A2 (pt)
CA (1)	CA2726281C (pt)
DK (1)	DK2291654T3 (pt)
ES (1)	ES2673005T3 (pt)
PT (1)	PT2291654T (pt)
TR (1)	TR201808152T4 (pt)
WO (1)	WO2009154695A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7932365B2 (en)	2003-11-08	2011-04-26	Pro Thera Biologics, Llc	Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
PT2291654T (pt)	2008-05-28	2018-06-15	Prothera Biologics Inc	Preparação e composição de proteínas inibidoras de interalfa do sangue
AU2010202125B1 (en)	2010-05-26	2010-09-02	Takeda Pharmaceutical Company Limited	A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en)	2010-05-26	2014-07-08	Baxter International Inc.	Removal of serine proteases by treatment with finely divided silicon dioxide
CN103119058A (zh)	2010-07-23	2013-05-22	巴克斯特国际公司	由血浆生产间-α-抑制蛋白(IAIP)
KR101443257B1 (ko) *	2011-10-18	2014-09-19	주식회사 종근당	낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
US9572872B2 (en) *	2012-09-09	2017-02-21	Prothera Biologics, Inc.	Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en)	2013-01-18	2014-07-24	Prothera Biologics	Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2015034566A1 (en) *	2013-09-04	2015-03-12	Emd Millipore Corporation	Protein a chromatography
EP3048899B1 (en) *	2013-09-25	2021-09-08	Bioverativ Therapeutics Inc.	On-column viral inactivation methods
CN104138374A (zh) *	2014-07-26	2014-11-12	滨州医学院	硫酸阿扎那韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用
EP3362464B1 (en) *	2015-10-15	2021-04-28	Plasma Technologies LLC	Methods for extracting proteins from blood plasma
CA3036553A1 (en)	2016-09-13	2018-03-22	Prothera Biologics, Inc.	Methods for treating pulmonary disease using inter-alpha inhibitor proteins
KR102587810B1 (ko) *	2017-04-25	2023-10-11	프로테라 바이오로직스, 인크.	인터-알파 억제제 단백질을 정량화하는 방법
US11040068B2 (en) *	2017-04-26	2021-06-22	Alkahest, Inc.	Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
IL274776B2 (en) *	2017-11-20	2025-02-01	Lonza Ag	Process and system for growing cell cultures while preventing lactate accumulation
CN112912065A (zh) *	2018-10-24	2021-06-04	普罗瑟拉生物公司	间α抑制剂蛋白及其使用方法
CN109900689B (zh) *	2019-03-28	2021-12-10	复星诊断科技(长沙)有限公司	抗干扰膜及肝功能联合测试条
JP2023549538A (ja) *	2020-11-16	2023-11-27	プロセラバイオロジクス，インク．	インターアルファインヒビタータンパク質の精製方法
WO2023089503A1 (en) *	2021-11-16	2023-05-25	Takeda Pharmaceutical Company Limited	Inter-alpha inhibitor protein formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4839298A (en) *	1986-02-14	1989-06-13	Akzo N.V.	Virus inactivating diluents used in immunoassays
ES2048263T3 (es)	1988-11-01	1994-03-16	Sanol Arznei Schwarz Gmbh	Composicion liofilizada de mdm y metodo para su fabricacion.
GB8928501D0 (en)	1989-12-18	1990-02-21	Unilever Plc	Reagents
US5166133A (en)	1991-04-17	1992-11-24	Cetus Corporation	Method for inhibing adhesion of white blood cells to endothelial cells
FR2706466B1 (fr)	1993-06-14	1995-08-25	Aetsrn	Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) *	1993-10-18	1995-12-29	Aetsrn	Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
JPH0953775A (ja)	1995-06-09	1997-02-25	Kubota Corp	埋設管路
WO1997004075A1 (en) *	1995-07-20	1997-02-06	New York University	Pharmaceutical compositions containing tsg-6 for treating inflammatory diseases and cancer-related pathologies and methods
WO2000006698A1 (en)	1998-07-30	2000-02-10	Human Genome Sciences, Inc.	98 human secreted proteins
US6673908B1 (en)	1999-02-22	2004-01-06	Nuvelo, Inc.	Tumor necrosis factor receptor 2
US6489128B1 (en)	2000-01-24	2002-12-03	Rhode Island Hospital, A Lifespan Partner	Methods for detecting cancer of the central nervous system
US6660482B1 (en)	2000-02-28	2003-12-09	Rhode Island Hospital	Inter-alpha-trypsin inhibitor as a marker for sepsis
JP2004511492A (ja) *	2000-10-13	2004-04-15	オクタファルマ　アクチェン　ゲゼルシャフト	ビクニンを含む血漿画分、その調製方法、およびその使用
EP1328260A2 (en)	2000-10-18	2003-07-23	Massachusetts Institute Of Technology	Methods and products related to pulmonary delivery of polysaccharides
IL155567A0 (en)	2000-12-08	2003-11-23	Genentech Inc	Method of diagnosing and treating cartilaginous disorders
GB0114709D0 (en) *	2001-06-15	2001-08-08	Pfizer Ltd	Stabilised formulations of amlodipine maleate
US20030027848A1 (en)	2001-06-15	2003-02-06	Anne Billotte	Stabilized formulations
US20040009212A1 (en) *	2002-01-30	2004-01-15	Pharma Power Biotec Co. Ltd.	Mucoadhesive thermoresponsive medicament-carrier composition
DE10204462A1 (de)	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
IL164152A0 (en) *	2002-03-26	2005-12-18	Teva Pharma	Drug microparticles
CA2518734A1 (en) *	2003-03-14	2004-09-30	Nirmal Mulye	A process for preparing sustained release tablets
AU2004275860A1 (en)	2003-09-23	2005-04-07	Pdl Biopharma, Inc.	Treatment of respiratory diseases with anti-IL-2 receptor antibodies
US7932365B2 (en) *	2003-11-08	2011-04-26	Pro Thera Biologics, Llc	Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
WO2005121163A2 (en)	2004-06-07	2005-12-22	Upfront Chromatography A/S	Isolation of plasma or serum proteins
US7939282B2 (en)	2004-10-21	2011-05-10	Rhode Island Hospital	Methods for detecting sepsis
CN101160133B (zh) *	2004-11-05	2013-01-09	普罗瑟拉生物公司	治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CA2999420A1 (en)	2005-09-27	2007-04-05	Tissuetech, Inc.	Amniotic membrane preparations and purified compositions and methods of use
CN101378782A (zh)	2005-12-21	2009-03-04	惠氏公司	粘度降低的蛋白质制剂及其用途
WO2008067655A1 (en)	2006-12-05	2008-06-12	Q6 Biomaterials Inc.	Biocompatible hydrogel-based scaffolds
PT2291654T (pt)	2008-05-28	2018-06-15	Prothera Biologics Inc	Preparação e composição de proteínas inibidoras de interalfa do sangue
HUE027953T2 (en)	2008-07-18	2017-01-30	A1M Pharma Ab	Medical use of the radical scavenger and antioxidant alpha-1 microglobulin
AU2009325088B2 (en)	2008-12-10	2014-06-19	Duke University	Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
US8772462B2 (en)	2010-05-26	2014-07-08	Baxter International Inc.	Removal of serine proteases by treatment with finely divided silicon dioxide
US9562906B2 (en)	2010-06-10	2017-02-07	National University Of Singapore	Methods for detection of gastric cancer
CN103119058A (zh)	2010-07-23	2013-05-22	巴克斯特国际公司	由血浆生产间-α-抑制蛋白(IAIP)
US9572872B2 (en)	2012-09-09	2017-02-21	Prothera Biologics, Inc.	Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en)	2013-01-18	2014-07-24	Prothera Biologics	Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material

2009
- 2009-05-28 PT PT97670087T patent/PT2291654T/pt unknown
- 2009-05-28 WO PCT/US2009/003291 patent/WO2009154695A1/en not_active Ceased
- 2009-05-28 CN CN200980129119.6A patent/CN102112876B/zh active Active
- 2009-05-28 CA CA2726281A patent/CA2726281C/en active Active
- 2009-05-28 KR KR1020167030334A patent/KR101828433B1/ko active Active
- 2009-05-28 TR TR2018/08152T patent/TR201808152T4/tr unknown
- 2009-05-28 KR KR1020107029406A patent/KR101714008B1/ko active Active
- 2009-05-28 US US12/995,141 patent/US9139641B2/en active Active
- 2009-05-28 BR BRPI0913949A patent/BRPI0913949A2/pt active IP Right Grant
- 2009-05-28 KR KR1020177027338A patent/KR20170116196A/ko not_active Ceased
- 2009-05-28 JP JP2011511643A patent/JP5793076B2/ja active Active
- 2009-05-28 CN CN201710066775.2A patent/CN106928346B/zh active Active
- 2009-05-28 DK DK09767008.7T patent/DK2291654T3/en active
- 2009-05-28 BR BR122020017577-0A patent/BR122020017577B1/pt active IP Right Grant
- 2009-05-28 EP EP09767008.7A patent/EP2291654B1/en active Active
- 2009-05-28 ES ES09767008.7T patent/ES2673005T3/es active Active
- 2009-05-28 AU AU2009260822A patent/AU2009260822B2/en active Active
2015
- 2015-04-09 JP JP2015080358A patent/JP6309915B2/ja active Active
- 2015-09-21 US US14/859,705 patent/US9758570B2/en active Active
2017
- 2017-02-22 US US15/439,328 patent/US10076559B2/en active Active
- 2017-06-27 JP JP2017124777A patent/JP2018008941A/ja active Pending

Also Published As

Publication number	Publication date
PT2291654T (pt)	2018-06-15
EP2291654A1 (en)	2011-03-09
CA2726281C (en)	2023-04-18
JP2018008941A (ja)	2018-01-18
JP2011524343A (ja)	2011-09-01
US9758570B2 (en)	2017-09-12
US20110190194A1 (en)	2011-08-04
KR101828433B1 (ko)	2018-03-29
WO2009154695A1 (en)	2009-12-23
JP5793076B2 (ja)	2015-10-14
CN106928346A (zh)	2017-07-07
AU2009260822A1 (en)	2009-12-23
CN106928346B (zh)	2021-09-07
EP2291654B1 (en)	2018-04-11
KR101714008B1 (ko)	2017-03-09
DK2291654T3 (en)	2018-06-14
US9139641B2 (en)	2015-09-22
US20160145318A1 (en)	2016-05-26
KR20110053404A (ko)	2011-05-23
CN102112876A (zh)	2011-06-29
KR20160129914A (ko)	2016-11-09
US20170157224A1 (en)	2017-06-08
BR122020017577B1 (pt)	2021-10-26
AU2009260822B2 (en)	2016-09-22
US10076559B2 (en)	2018-09-18
KR20170116196A (ko)	2017-10-18
EP2291654A4 (en)	2011-08-24
CA2726281A1 (en)	2009-12-23
JP2015155434A (ja)	2015-08-27
ES2673005T3 (es)	2018-06-19
TR201808152T4 (tr)	2018-07-23
JP6309915B2 (ja)	2018-04-11
CN102112876B (zh)	2017-12-08

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-02	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001
2020-05-05	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-06-02	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-12-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-01-19	B25D	Requested change of name of applicant approved	Owner name: PROTHERA BIOLOGICS, INC. (US)
2021-02-09	B25G	Requested change of headquarter approved	Owner name: PROTHERA BIOLOGICS, INC. (US)
2021-05-04	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-07-13	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2026-02-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

Publication	Publication Date	Title
BRPI0913949A2 (pt)	2015-10-20	preparação e composição de proteínas inibidoras inter-alfa a partir de sangue
DK2379600T4 (da)	2021-01-04	Antistoffer mod tissue factor pathway inhibitor
FR16C1026I2 (fr)	2018-01-19	Inhibiteurs de la replication du virus de l'hepatite c
EP2377028A4 (en)	2012-08-29	CHANGE OF COMMANDS
DK2041270T3 (da)	2014-01-27	Fremstilling af glycoproteiner
PT2376537T (pt)	2016-12-26	Anticorpos humanos contra fator tecidual humano
EP2272817A4 (en)	2011-12-14	PAI-1 INHIBITORS
DK2231606T3 (da)	2013-05-13	Fremgangsmåder til fremstilling af cycloalkylcarboxamidopyridinbenzoesyrer
EP2092445A4 (en)	2011-01-19	NEGOTIATING SEARCH RESULTS
PT2376533T (pt)	2016-07-13	Formulação de anticorpos
EP2356139A4 (en)	2013-01-09	LIGURE COMBINED POLYPEPTIDES
IL208979B (en)	2018-02-28	Humanized antibodies against human interferon-alpha
SMT201600314B (it)	2016-11-10	Coniugati di proteina di coagulazione di sangue
DK2034830T3 (da)	2014-10-27	Anti-vla-1-antistof til behandling af slagtilfælde
BRPI0907109A2 (pt)	2016-05-03	lenço dental e método
EP2463316A4 (en)	2014-01-22	acrylate composition
EP2237793A4 (en)	2013-07-31	CATHEPSIN-B INHIBITORS
EP2110789A4 (en)	2010-12-01	PAPER MONEY PROCESSOR
DK2154149T3 (da)	2019-10-14	En trunkeret l1-protein af human papillomavirus 6
DE602007014179D1 (de)	2011-06-09	Herstellung von polytrimethylen-etherglykol
EP2462237A4 (en)	2013-07-03	METHOD FOR IMPROVING THE EXPRESSION OF RECOMBINANT PROTEINS
DK2005182T3 (da)	2013-08-05	Kliniske korrelater
EP2350857A4 (en)	2012-05-23	BOOTSTRAP REDENZVOUSPUNKTERING
IT1395539B1 (it)	2012-09-28	Piede d'appoggio
DE602008005536D1 (de)	2011-04-28	Herstellung von MnB12H12